Skip to main content

Table 2 Doses of tolvaptan administered

From: Magnetic resonance imaging is effective for evaluating the therapeutic effect of tolvaptan on total kidney volume in patients with autosomal dominant polycystic kidney disease

Protein uria < 0.15 g/gCr 0.15-0.49 g/gCr > 0.50 g/gCr
CKD stage     
GFR (mL/min/1.73m2) 90 120 (case 1)   
60~ 89    
45~ 59 90/90 (case 2 and 3)   
30~ 44 120/90 (case 4 and 5)   
15~ 29   90 (case 6)  
< 15    
     (mg/day)
  1. Cases 1 and 4 were treated with 120 mg/day tolvaptan. Cases 2, 3, 5, and 6 were treated with 90 mg/day tolvaptan